All articles by Refna Tharayil
Refna Tharayil
FDA accepts supplemental biologics license application for Roche’s Gazyva/Gazyvaro for treatment of lupus nephritis
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody in a randomised phase III study to demonstrate a CRR benefit in lupus nephritis
FairJourney Biologics acquires Charles River Laboratories South San Francisco facility
Acquisition of Charles River site, previously Distributed Bio, strengthens antibody discovery capabilities with SuperHuman libraries and Yeast Display platform